Peter Attia· MD
And as a characteristic event in CML, that you would see this in at least 95% of cases, this massive chromosomal shift, but not others.
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
And as a characteristic event in CML, that you would see this in at least 95% of cases, this massive chromosomal shift, but not others.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
But a molecular insight came in the 1970s that basically there was a very common kind of macroscopic, if you will, chromosomal change where one part of a chromosome would vary stereotypically 95% likelihood that a CML patient would have the repositioning of one portion of a chromosome to another.
Whole-body MRI screening in healthy adults produces more incidentaloma harm than cancer-mortality benefit.
Starting colonoscopy screening at 45 (vs 50) prevents enough early-onset cancers to justify the population cost.
Multi-cancer liquid-biopsy tests like Galleri detect early cancers at a stage that meaningfully improves survival.